1 / 3

Advancements in Clinical Development Process: Bridging Studies and Global Strategies

This presentation outlines the current status and future goals in the clinical development process within the ICH E5 environment. Dr. Iwasaki discusses classical bridging strategies, the necessity of prospective planning, and efficient methodologies for legacy products. Key topics include transitioning from bridging to global studies, pharmacological bridging, and simultaneous filing requirements. The talk emphasizes collaborative global development, regional protocol modifications, and the importance of integrated global reviews, ultimately aiming for harmonized drug development across multiple regions.

dareh
Télécharger la présentation

Advancements in Clinical Development Process: Bridging Studies and Global Strategies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Development Process in ICH E5 Environment (1) • Current status ; Classical bridging • Bridging study in PIIb (DFS) • Aiming skipping PIII • Most efficient in legacy products • Only acceptable on prospective planning • Need to reduce the initial GAP for simultaneous filing Dr.Iwasaki / 3rd K-H Symposium

  2. Clinical Development Process in ICH E5 Environment (2) • Current Target ; From Bridging to Global Study • P.I ; one site study / one protocol with two sites • PIIa ; Pharmacological bridging • Participation in Global studies for simultaneous filing 1, Conditions for starting PI 2, Validity of surrogate marker in PIIa 3, Integrated Global development plan with Japan input 4, Regional modification of the study protocol 5, Sample size - Only from Japan, or from Asian region Dr.Iwasaki / 3rd K-H Symposium

  3. Clinical Development Process in ICH E5 Environment (3) • Future Target ; Global Drug Development • Core data from pivotal global studies • Regional studies for all sites • Simultaneous filing with same documents • Regional adjustment of labeling • Need to consider Integrated Global Review Dr.Iwasaki / 3rd K-H Symposium

More Related